Index
Module 6 • Infectious Diseases
Infectious Diseases I
97%
Core Content
Infectious Diseases I
Jacob Schwarz ~2 min read Module 6 of 20
59
/ 61

Infectious Diseases I

19Answer: D

This patient likely has severe influenza amid a local

seasonal outbreak. Local infection patterns suggest

a prevalence of influenza A and B strains. Empiric

influenza-specific

therapy

against

these

strains

should be initiated in patients with severe influenza

before confirmatory test results are known to avoid a

delay in appropriate therapy (Answer B is incorrect).

Neuraminidase-based therapy is recommended for

modern influenza A and B stains (Answer D is correct;

Answer C is incorrect). Even if they are outside 48 hours

from symptom onset, patients with severe influenza

have benefited from therapy initiated beyond this period

(Answer A is incorrect).

20Answer: B

Neuraminidase inhibitors are the mainstay of treat-

ment because resistance to adamantanes has developed

in contemporary influenza A strains, and these agents

have no antiviral activity against influenza B (Answer

A is incorrect). Inhaled zanamivir is not appropriate

for administration to mechanically ventilated patients

(Answer C is incorrect). Intravenous peramivir also is

available; however, data are limited for its use in criti-

cally ill patients with severe, complicated influenza

infection (Answer D is incorrect). Enteral oseltamivir

is the preferred therapy for current influenza B strains

in critically ill patients with severe, complicated influ-

enza infection (Answer B is correct). Clinicians should

be mindful of the need for renal dosage adjustment, if

necessary.

21Answer: D

Remdesivir is recommended for patients requiring

supplemental oxygen. On the basis of the results of the

ACTT study showing no difference in recovery time or

mortality in more severe subgroups, the NIH guidelines

do not recommend for or against remdesivir in patients

requiring high-flow oxygen, MV, or ECMO (Answer D

is correct; Answers A and C are incorrect). If remdesivir

is initiated before advancing to MV, it is recommended

to continue and complete therapy. Available evidence

guidelines do not suggest increased adverse effects with

remdesivir between less and more severely ill patients

(Answer B is incorrect).

HD Video Explanation β€” Synchronized with PDF
Starts at: minute 58 Open on YouTube